Have a personal or library account? Click to login
Analysis of the routine use of polyethylene glycol (PEG) as an enhancement medium Cover

Analysis of the routine use of polyethylene glycol (PEG) as an enhancement medium

Paid access
|Nov 2020

Abstract

This study compared the performance of polyethylene glycol (PEG) and low-ionic saline solutions (USS) as enhancement media for routine use in a large transfusion service, A PEG additive solution (PEG plus LISS) was compared to a LISS additive (LISS plus polymers) and to an albumin-indirect antiglobulin test (A-IAT). Fifty serum samples containing clinically significant alloantibodies and fifty samples without alloantibodies were tested. Following an acute hemolytic transfusion reaction (HTR) involving an anti-K that was not detected with LISS but was retrospectively found to be reactive with PEG, an additional 151 samples received for antibody screening were prospectively evaluated in parallel using PEG and LISS. PEG detected all clinically significant antibodies in the 50 previously tested samples, with mean reactivity scores greater than LISS or A-IAT. In the prospective study, PEG detected 35 clinically significant antibodies and 10 clinically insignificant antibodies, while LISS detected only 15 clinically significant antibodies and 33 clinically insignificant antibodies. PEG appears to increase detection of significant antibodies while decreasing detection of insignificant antibodies. PEG was therefore substituted for LISS as an enhancement medium and has been in routine use for 12 months, with no reported acute or anamnestic HTRs in 6,353 transfusions.

DOI: https://doi.org/10.21307/immunohematology-2019-779 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 11 - 13
Published on: Nov 17, 2020
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 V.J. Barrett, J.R. Stubbs, K. Stuardi, A. Hollis, L. Clear, published by American National Red Cross
This work is licensed under the Creative Commons License.